ClinicalTrials.Veeva

Menu
C

Carolina BioOncology Institute | Huntersville, NC

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

ABBV-181
Budigalimab
ABBV-927
Nivolumab
Pembrolizumab
Etrumadenant
Taxane
TRE-515
Aldesleukin
MDK-703

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

28 of 33 total trials

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

This is a Phase 1, open-label, 2-part, multi-center study evaluating the safety, tolerability, PK, pharmacodynamics (PD), immunogenicity, and antitum...

Active, not recruiting
Gastric Cancer
Ovarian Cancer
Drug: CUE-102

The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or w...

Enrolling
Advanced Solid Tumor Cancer
Drug: Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)
Drug: ABBV-CLS-484

The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein ca...

Enrolling
Solid Tumor, Adult
Drug: CRB-701

This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tol...

Active, not recruiting
Advanced Solid Tumors Cancer
Drug: ABBV-927
Drug: ABBV-181

ASP1012 is a type of virus called an oncolytic virus which is used to treat some cancers.ASP1012 was changed in a laboratory to infect and kill cance...

Enrolling
Solid Tumor
Drug: ASP1012
Drug: Pembrolizumab

The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in part...

Enrolling
Advanced Solid Tumors
Drug: Capecitabine
Drug: Docetaxel

The purpose of this study is to assess the safety and tolerability of BMS-986406 administered alone, in combination with nivolumab, or in combination...

Active, not recruiting
Advanced Cancer
Biological: Nivolumab
Drug: Pemetrexed

The purpose of this study is to evaluate BMS-986442 in combination with nivolumab (with or without chemotherapy) for its antitumor efficacy and benef...

Active, not recruiting
Advanced Solid Tumors
Non-small Cell Lung Cancer
Drug: Carboplatin
Drug: Pemexetred

CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumor...

Enrolling
Advanced Solid Tumor
Drug: CLN-619
Drug: Pembrolizumab

Prostate cancer has the second highest incidence rate and is the fifth leading cause of cancer-related deaths among men worldwide. The purpose of thi...

Enrolling
Metastatic Castration-Resistant Prostate Cancer
Drug: ABBV-969

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolera...

Enrolling
Solid Tumors
Drug: Budigalimab
Drug: ABBV-303

A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) an...

Active, not recruiting
Advanced Solid Tumors
Non-small-cell-lung-cancer (NSCLC)
Drug: ABBV-368
Drug: ABBV-927

This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab...

Active, not recruiting
Solid Tumor, Unspecified, Adult
Drug: Domvanalimab
Drug: Zimberelimab

An open-label, dose-escalation (Part 1), dose-expansion (Part 2) study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-...

Active, not recruiting
Advanced Solid Tumors
Drug: ABBV-155
Drug: Paclitaxel

This is a first-in-human, Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, p...

Enrolling
Pancreatic Ductal Adenocarcinoma
Non Small Cell Lung Cancer
Drug: PT199
Drug: Tislelizumab

RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designe...

Enrolling
Advanced Cancer
Drug: RBS2418

The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 in adult part...

Enrolling
Solid Tumor, Adult
Drug: CX-2051

NUV-868-01 is a first-in human, open- label, Phase 1/2 dose escalation and expansion study in patients with advanced solid tumors. The Phase 1 and 1b...

Enrolling
Prostate Neoplasm
Advanced Solid Tumor
Drug: Enzalutamide
Drug: NUV-868

TRE-515 is a first-in-class small molecule inhibitor of deoxycytidine kinase (dCK) that is being developed for oral administration in patients with s...

Enrolling
Oncology
Solid Tumor, Adult
Drug: TRE-515

This is a first-in-human (FIH), open label Phase 1/1b study in patients with advanced metastatic solid tumors refractory to standard treatment. Phase...

Enrolling
Cancer
Drug: Antibody-Drug Conjugate

Trial sponsors

AbbVie logo
Arcus Biosciences logo
Bristol-Myers Squibb (BMS) logo
N
Astellas logo
A
BioNTech logo
Calico Life Sciences logo
C
C

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems